Neurology® Podcast
Monoclonal Antibody to PACAP for Migraine Prevention
Sep 12, 2024
Dr. Tesha Monteith, an expert on PACAP biology, joins Dr. Messoud Ashina, a specialist in migraine therapies, to discuss groundbreaking research on monoclonal antibodies for migraine prevention. They dive into PACAP's crucial role in migraine development and the challenges of treatment research. The conversation includes insights from recent clinical trials assessing the effectiveness of PACAP-targeted therapies, the potential for combination treatments, and the future of migraine management. An engaging exploration of a promising new frontier in headache treatment!
24:55
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- PACAP is a crucial factor in migraine pathogenesis and has been shown to trigger migraine attacks through its dual role in vasodilation and pain transmission.
- A recent study demonstrated that a monoclonal antibody targeting PACAP significantly reduces migraine days in patients, indicating a promising new treatment approach for chronic and episodic migraines.
Deep dives
Understanding PACAP's Role in Migraine Biology
PACAP, or pituitary adenylate cyclase-activating polypeptide, is identified as a significant contributor to migraine pathogenesis. Research shows that infusions of PACAP can trigger migraine attacks, leading to extensive studies to understand its mechanisms. PACAP plays a dual role as both a strong vasodilator and a mediator of pain transmission and neuroinflammation, which complicates its action in migraine. Previous studies have demonstrated that different isoforms of PACAP can induce migraine symptoms, emphasizing its importance in the clinical context of migraine management.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
